MRK.TO Merck CDR (CAD Hedged)
- Market cap
- -
- P/E
- 147.9x
- P/B
- 7.91x
- ROE
- -1.5%
- Dividend yield
- 2.67%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MRK.TO undervalued?
Graham numberThe Graham number of Merck CDR (CAD Hedged) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Merck CDR (CAD Hedged) fundamental analysis
No fundamental analysis for Merck CDR (CAD Hedged) yet.
Merck CDR (CAD Hedged) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Merck CDR (CAD Hedged)
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and …
Full company profileMerck CDR (CAD Hedged) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Merck CDR (CAD Hedged) annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 59.3B | 60.1B | 64.2B | 65.0B | 68.0B |
| Gross Profit | 42.1B | 44.2B | 49.5B | 50.1B | 50.0B |
| Operating Income | 17.9B | 1.78B | 19.9B | 21.2B | 2.85B |
| EBITDA | 21.3B | 6.91B | 25.7B | 28.3B | 10.4B |
| Net Income | 14.5B | 365M | 17.1B | 18.3B | -680M |
| EPS | 5.72 | 0.14 | 6.77 | 7.38 | -0.28 |
| Balance Sheet | |||||
| Total Assets | 109B | 107B | 117B | 137B | 133B |
| Total Liabilities | 63.2B | 69.1B | 70.8B | 84.3B | 87.8B |
| Shareholders' Equity | 46.0B | 37.6B | 46.3B | 52.6B | 44.9B |
| Cash & Short-term Investments | 13.2B | 7.09B | 13.7B | 14.6B | 9.55B |
| Cash Flow | |||||
| Operating Cash Flow | 19.1B | 13.0B | 21.5B | 16.5B | 21.1B |
| Capital Expenditure | 4.39B | 3.86B | 3.37B | 4.11B | 3.90B |
| Free Cash Flow | 14.7B | 9.14B | 18.1B | 12.4B | 17.2B |
| Ratios | |||||
| ROE | 31.6% | 1.0% | 37.0% | 34.7% | -1.5% |
| ROA | 13.3% | 0.3% | 14.6% | 13.3% | -0.5% |
| Net Profit Margin | 24.5% | 0.6% | 26.7% | 28.1% | -1.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Merck CDR (CAD Hedged) dividends
- Dividend yield
- 2.67%
- Forward dividend
- -
- Payout ratio
- 44.8%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 8.18B | 3.30 | 44.8% |
| 2024 | USD 7.84B | 3.10 | 45.8% |
| 2023 | USD 7.45B | 2.94 | 2,039.7% |
| 2022 | USD 7.01B | 2.76 | 48.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Merck CDR (CAD Hedged)
Ownership data of Merck CDR (CAD Hedged) is not available yet.
Merck CDR (CAD Hedged) company profile
- Company name
- Merck CDR (CAD Hedged)
- Ticker
- MRK.TO
- Exchange
- Toronto Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 73,000
- Fiscal year end
- December
- Address
- 126 East Lincoln Avenue, Rahway, NJ, United States, 07065
- Phone
- 908 740 4000
- Website
- merck.com
About Merck CDR (CAD Hedged)
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Merck CDR (CAD Hedged) management
10- Mr. Robert M. Davis J.D.Chairman, President & CEO · born 1967
- Ms. Caroline A. LitchfieldExecutive VP & CFO · born 1969
- Ms. Betty D. LarsonExecutive VP & Chief Human Resources Officer · born 1976
- Mr. Richard R. DeLuca Jr.Executive VP & President of Merck Animal Health · born 1963
- Dr. Dean Y. Li M.D., Ph.D.Executive VP & President of Merck Research Laboratories · born 1963
- Mr. Dalton E. Smart IIISenior VP of Finance, Principal Accounting Officer & Global Controller · born 1967
- Mr. David Michael WilliamsExecutive VP and Chief Information & Digital Officer · born 1969
- Mr. Peter DannenbaumVice President of Investor Relations
- Ms. Jennifer L. Zachary J.D.Executive VP & General Counsel · born 1978
- Mr. Sanat ChattopadhyayExecutive VP & President of Merck Manufacturing Division · born 1960